Thermo Fisher Scientific (NYSE:TMO) Stock Unloaded Sen. Markwayne Mullin

Senator Markwayne Mullin (R-Oklahoma) recently sold shares of Thermo Fisher Scientific Inc. NYSE: TMO. In a filing disclosed on May 12th, the Senator disclosed that they had sold between $50,001 and $100,000 in Thermo Fisher Scientific stock on April 8th.

Senator Markwayne Mullin also recently made the following trade(s):

• Sold $15,001 - $50,000 in shares of Texas Instruments NASDAQ: TXN on 4/8/2025.
• Sold $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/8/2025.
• Sold $50,001 - $100,000 in shares of Lam Research NASDAQ: LRCX on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Chevron NYSE: CVX on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/8/2025.
• Sold $15,001 - $50,000 in shares of ConocoPhillips NYSE: COP on 4/8/2025.
• Sold $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/8/2025.
• Sold $15,001 - $50,000 in shares of Adobe NASDAQ: ADBE on 4/8/2025.
• Sold $50,001 - $100,000 in shares of Valero Energy NYSE: VLO on 4/8/2025.
• Purchased $15,001 - $50,000 in shares of Capital One Financial NYSE: COF on 3/19/2025.

Thermo Fisher Scientific Price Performance

Shares of TMO traded down $1.78 during midday trading on Thursday, hitting $404.27. The company's stock had a trading volume of 4,128,328 shares, compared to its average volume of 1,834,804. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. Thermo Fisher Scientific Inc. has a one year low of $390.56 and a one year high of $627.88. The stock has a market capitalization of $152.61 billion, a price-to-earnings ratio of 24.46, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company's fifty day simple moving average is $458.36 and its two-hundred day simple moving average is $512.38.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The firm had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the previous year, the firm posted $5.11 EPS. The company's revenue for the quarter was up .2% compared to the same quarter last year. As a group, equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Shareholders of record on Friday, March 14th were paid a dividend of $0.43 per share. The ex-dividend date was Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.43%. Thermo Fisher Scientific's dividend payout ratio is presently 10.09%.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 3,775 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the sale, the senior vice president now directly owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the sale, the chief executive officer now directly owns 115,174 shares in the company, valued at $59,506,950.58. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is owned by company insiders.

Hedge Funds Weigh In On Thermo Fisher Scientific

Hedge funds have recently added to or reduced their stakes in the business. Cypress Advisory Group LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $253,000. S.E.E.D. Planning Group LLC raised its position in shares of Thermo Fisher Scientific by 6.2% during the 4th quarter. S.E.E.D. Planning Group LLC now owns 10,626 shares of the medical research company's stock worth $5,528,000 after buying an additional 618 shares in the last quarter. Czech National Bank grew its position in Thermo Fisher Scientific by 6.6% in the fourth quarter. Czech National Bank now owns 82,934 shares of the medical research company's stock worth $43,145,000 after buying an additional 5,118 shares during the last quarter. Granite Bay Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth about $4,758,000. Finally, Courier Capital LLC boosted its position in shares of Thermo Fisher Scientific by 148.8% in the fourth quarter. Courier Capital LLC now owns 20,914 shares of the medical research company's stock worth $10,880,000 after buying an additional 12,509 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TMO. Evercore ISI decreased their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Barclays lowered their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. Scotiabank lowered their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating for the company in a research note on Friday, April 25th. Citigroup dropped their price objective on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating on the stock in a report on Tuesday, March 4th. Finally, The Goldman Sachs Group set a $610.00 target price on Thermo Fisher Scientific and gave the company a "buy" rating in a report on Wednesday, April 23rd. Five investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $607.43.

About Senator Mullin

Markwayne Mullin (Republican Party) is a member of the U.S. Senate from Oklahoma. He assumed office on January 11, 2023. His current term ends on January 3, 2027. Mullin (Republican Party) ran in a special election to the U.S. Senate to represent Oklahoma. He won in the special general election on November 8, 2022. Mullin is a member of the Cherokee Nation and one of four Native American members of the 116th Congress. At the age of 20, Mullin took over his father's plumbing business. He is also a former professional mixed martial artist. Markwayne Mullin graduated from Stilwell High School. Mullin earned an associate degree in construction technology from Oklahoma State University Institute of Technology. His career experience includes owning and founding multiple businesses.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.